Summit Therapeutics Ownership | Who Owns Summit Therapeutics?


OverviewForecastFinancialsChartTranscripts

Summit Therapeutics Ownership Summary


Summit Therapeutics is owned by 10.28% institutional investors, 84.36% insiders, and 5.35% retail investors. Baker bros. advisors lp is the largest institutional shareholder, holding 3.31% of SMMT shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 0.46% of its assets in Summit Therapeutics shares.

SMMT Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockSummit Therapeutics10.28%84.36%5.35%
SectorHealthcare Stocks 47.06%8.01%44.93%
IndustryBiotech Stocks 44.97%7.82%47.21%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Baker bros. advisors lp23.22M3.31%$181.13M
Vanguard group8.82M1.26%$68.78M
Blackrock7.90M1.13%$61.61M
Fmr7.57M1.08%$59.01M
State street4.12M0.59%$32.16M
Geode capital management2.96M0.42%$23.12M
Price t rowe associates inc /md/2.04M0.29%$15.93M
Millennium management1.94M0.28%$15.15M
Balyasny asset management1.01M0.14%$7.88M
Northern trust960.30K0.14%$7.49M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Baker bros. advisors lp23.22M2.31%$181.13M
Qvt financial lp575.71K0.42%$4.49M
Wealth management partners42.00K0.16%$327.60K
Vance wealth39.27K0.13%$306.27K
Sargent investment group72.00K0.11%$561.60K
China universal asset management82.47K0.09%$643.29K
Sectoral asset management25.00K0.08%$195.00K
Caption management499.10K0.06%$3.89M
Fullcircle wealth12.21K0.06%$121.85K
Hoylecohen86.41K0.05%$673.98K

Top Buyers

HolderShares% AssetsChange
Baker bros. advisors lp23.22M2.31%23.22M
Price t rowe associates inc /md/2.04M0.00%2.01M
Millennium management1.94M0.01%1.94M
Vanguard group8.82M0.00%1.55M
Balyasny asset management1.01M0.01%1.01M

Top Sellers

HolderShares% AssetsChange
State street4.12M0.00%-3.99M
Blackrock7.90M0.00%-1.92M
Anson funds management lp---941.91K
Steward partners investment advisory---606.50K
Bank of montreal /can/---589.57K

New Positions

HolderShares% AssetsChangeValue
Baker bros. advisors lp23.22M2.31%23.22M$181.13M
Millennium management1.94M0.01%1.94M$15.15M
Balyasny asset management1.01M0.01%1.01M$7.88M
Qvt financial lp575.71K0.42%575.71K$4.49M
Caption management499.10K0.06%499.10K$3.89M

Sold Out

HolderChange
Citadel advisors-5.00
Pacer advisors-944.00
National bank of canada /fi/-1.60K
Metropolitan life insurance co/ny-6.56K
Quinn opportunity partners-11.00K

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 202413123.58%72,166,50145.37%1016.02%6410.34%4573.08%
Mar 31, 20241069.28%49,642,03954.58%837.82%5828.89%2636.84%
Dec 31, 2023973.19%32,113,817-0.21%421.63%457.14%19-
Sep 30, 202394-7.84%32,181,292-7.57%45.44%42-28.81%19-9.52%
Jun 30, 20231023.03%34,817,56665.75%929.84%59-7.81%2150.00%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv3.41M0.46%-14.85K
Fidelity Select Biotechnology3.36M0.46%-324.50K
Vanguard Small Cap Index2.72M0.37%5.35K
iShares Russell 2000 ETF2.26M0.31%-5.07K
Vanguard Institutional Extnd Mkt Idx Tr2.06M0.28%109.93K
Vanguard Small Cap Value Index Inv1.84M0.25%-636.00
SPDR® S&P Biotech ETF1.19M0.16%13.23K
Fidelity Small Cap Index895.69K0.12%-22.45K
Fidelity Growth Compy Commingled Pl S868.21K0.12%146.69K
Fidelity Extended Market Index800.37K0.11%40.49K

Recent Insider Transactions


DateNameRoleActivityValue
Mar 27, 2024Zanganeh Mahkam Chief Executive OfficerBuy$127.67K
Mar 27, 2024Zanganeh Mahkam Chief Executive OfficerBuy$74.20K
Mar 26, 2024Zanganeh Mahkam Chief Executive OfficerBuy$112.50K
Mar 27, 2024Zanganeh Mahkam Chief Executive OfficerBuy$96.72K
Mar 26, 2024Dhingra Ankur Chief Financial OfficerBuy$375.00K

Insider Transactions Trends


DateBuySell
2024 Q4--
2024 Q3--
2024 Q2--
2024 Q15-
2023 Q44-

SMMT Ownership FAQ


Who Owns Summit Therapeutics?

Summit Therapeutics shareholders are primarily institutional investors at 10.28%, followed by 84.36% insiders and 5.36% retail investors. The average institutional ownership in Summit Therapeutics's industry, Biotech Stocks , is 44.97%, which Summit Therapeutics falls below.

Who owns the most shares of Summit Therapeutics?

Summit Therapeutics’s largest shareholders are Baker bros. advisors lp (23.22M shares, 3.31%), Vanguard group (8.82M shares, 1.26%), and Blackrock (7.9M shares, 1.13%). Together, they hold 5.69% of Summit Therapeutics’s total shares outstanding.

Does Blackrock own Summit Therapeutics?

Yes, BlackRock owns 1.13% of Summit Therapeutics, totaling 7.9M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 61.61M$. In the last quarter, BlackRock decreased its holdings by -1.925M shares, a -19.59% change.

Who is Summit Therapeutics’s biggest shareholder by percentage of total assets invested?

Baker bros. advisors lp is Summit Therapeutics’s biggest shareholder by percentage of total assets invested, with 2.31% of its assets in 23.22M Summit Therapeutics shares, valued at 181.13M$.

Who is the top mutual fund holder of Summit Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Summit Therapeutics shares, with 0.46% of its total shares outstanding invested in 3.41M Summit Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools